Orano Med, a major player in the development of targeted alpha therapies

One ambition: to position Orano Med as a key player in targeted alpha therapy

Founded on an unrivalled expertise in extracting and purifying lead-212 (²¹²Pb), Orano Med is using the element’s alpha-emitter properties to develop a new generation of targeted cancer therapies. This approach, known as targeted alpha therapy, couples ²¹²Pb with a variety of biological molecules (including peptides and antibodies) that selectively target cancer cells, thus limiting the impact on the surrounding healthy cells.

With a substantial portfolio of treatments under development that can target a variety of cancerous tumors, and a reliable ²¹²Pb supply chain, Orano Med aims to lead the way in targeted alpha therapies, in particular for patients for whom currently there is no therapeutic solution.

• Unique expertise in extracting and purifying ²¹²Pb.
• Phase II clinical trials under way with promising results for the treatment of neuroendocrine tumors. Another Phase-I clinical trial in progress.
• Around ten international scientific partners, and other in-house developments restricted to Orano Med.

• 80 employees in France and the United States

• 2 high-purity production units: in France, the Maurice Tubiana Laboratory, and in the United States, the Domestic Distribution and Purification Unit.

• 2 dedicated R&D centers, one in France and the other in the United States.

• 1 facility under construction for producing and distributing radiopharmaceuticals (ATLab) in the United States

• 120 doses of treatment based on ²¹²Pb produced and administered to over 50 patients during the current clinical trials.

• 3 awards for research work: prize from the Bill Clinton Foundation; Marie Curie Medal from the French Nuclear Society (SFEN); Healthtech award (biotechnology category) from France Biotech.